Literature DB >> 32693135

Effects of chitosan and oligochitosans on the phosphatidylinositol 3-kinase-AKT pathway in cancer therapy.

Elaheh Amirani1, Jamal Hallajzadeh2, Zatollah Asemi3, Mohammad Ali Mansournia4, Bahman Yousefi5.   

Abstract

Phosphatidylinositol 3-kinase (PI3K)-AKT pathway is one of the most important kinase signaling networks in the context of cancer development and treatment. Aberrant activation of AKT, the central mediator of this pathway, has been implicated in numerous malignancies including endometrial, hepatocellular, breast, colorectal, prostate, and, cervical cancer. Thus regulation and blockage of this kinase and its key target nodes is an attractive approach in cancer therapy and diverse efforts have been done to achieve this aim. Chitosan is a carbohydrate with multiple interesting applications in cancer diagnosis and treatment strategies. This bioactive polymer and its derivative oligomers commonly used in drug/DNA delivery methods due to their functional properties which improve efficiency of delivery systems. Further, these compounds exert anti-tumor roles through the stimulation of apoptosis, immune enhancing potency, anti-oxidative features and anti-angiogenic roles. Due to the importance of PI3K-AKT signaling in cancer targeting and treatment resistance, this review discusses the involvement of chitosan, oligochitosaccharides and carriers based on these chemicals in the regulation of this pathway in different tumors.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cancer; Chitosan; Delivery system; Oligochitosans; PI3K-AKT

Mesh:

Substances:

Year:  2020        PMID: 32693135     DOI: 10.1016/j.ijbiomac.2020.07.137

Source DB:  PubMed          Journal:  Int J Biol Macromol        ISSN: 0141-8130            Impact factor:   6.953


  7 in total

Review 1.  Bifunctional scaffolds for tumor therapy and bone regeneration: Synergistic effect and interplay between therapeutic agents and scaffold materials.

Authors:  Jiongpeng Yuan; Zhaoyi Ye; Yaoxun Zeng; Zhenxing Pan; ZhenZhen Feng; Ying Bao; Yushan Li; Xujie Liu; Yan He; Qingling Feng
Journal:  Mater Today Bio       Date:  2022-06-09

2.  Chitooligosaccharides Improve the Efficacy of Checkpoint Inhibitors in a Mouse Model of Lung Cancer.

Authors:  Astrid Zedlitz Johansen; Marco Carretta; Marie-Louise Thorseth; Shawez Khan; Klaire Yixin Fjæstad; Christian Beltoft Brøchner; Hannes Linder; Christina Ankjærgaard; Marco Donia; Inna Chen; Dorte Lisbet Nielsen; Claus Preibisch Behrens; Daniel Hargbøl Madsen
Journal:  Pharmaceutics       Date:  2022-05-12       Impact factor: 6.525

Review 3.  Recent Advances in Chitosan and its Derivatives in Cancer Treatment.

Authors:  Jingxian Ding; Yonghong Guo
Journal:  Front Pharmacol       Date:  2022-04-28       Impact factor: 5.988

4.  Combination of Sodium Cantharidinate with Cisplatin Synergistically Hampers Growth of Cervical Cancer.

Authors:  Xiangxun Chen; Mengxi Zhou; Wenjie Fan; Mingwei Yang; Lin Yang
Journal:  Drug Des Devel Ther       Date:  2021-01-13       Impact factor: 4.162

5.  Recombinant CCL17-dependent CCR4 activation alleviates neuroinflammation and neuronal apoptosis through the PI3K/AKT/Foxo1 signaling pathway after ICH in mice.

Authors:  Shuixiang Deng; Peng Jin; Prativa Sherchan; Shengpeng Liu; Yuhui Cui; Lei Huang; John H Zhang; Ye Gong; Jiping Tang
Journal:  J Neuroinflammation       Date:  2021-03-01       Impact factor: 8.322

Review 6.  The cancer metabolic reprogramming and immune response.

Authors:  Longzheng Xia; Linda Oyang; Jinguan Lin; Shiming Tan; Yaqian Han; Nayiyuan Wu; Pin Yi; Lu Tang; Qing Pan; Shan Rao; Jiaxin Liang; Yanyan Tang; Min Su; Xia Luo; Yiqing Yang; Yingrui Shi; Hui Wang; Yujuan Zhou; Qianjin Liao
Journal:  Mol Cancer       Date:  2021-02-05       Impact factor: 27.401

Review 7.  Progress in Research of Chitosan Chemical Modification Technologies and Their Applications.

Authors:  Qizhou Chen; Yi Qi; Yuwei Jiang; Weiyan Quan; Hui Luo; Kefeng Wu; Sidong Li; Qianqian Ouyang
Journal:  Mar Drugs       Date:  2022-08-21       Impact factor: 6.085

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.